Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Effects of Psilocybin for Patients with Psychogenic Non-Epileptic Seizures (PNES)

Verified siteInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a treatment for individuals experiencing psychogenic non-epileptic seizures (CNEP). These seizures are episodes that resemble epileptic seizures but are not caused by electrical disruptions in the brain. The treatment being tested is a single dose of psilocybin, a substance that is being explored for its potential effects on the brain.

The purpose of the study is to understand how a single dose of psilocybin affects brain activity related to cognitive control, which is the brain's ability to manage thoughts and actions, in patients with CNEP. This will be assessed using a technique called MRI (Magnetic Resonance Imaging), which allows researchers to see detailed images of the brain. Participants will undergo an emotional task known as the Go-No Go task, which helps measure cognitive control, before and after receiving psilocybin.

During the study, participants will receive a single dose of psilocybin in capsule form. Brain activity will be monitored before and after the treatment using MRI scans. The study will also track changes in the frequency of seizures and other related symptoms over a period of time. This research aims to provide insights into how psilocybin might influence brain function and potentially help manage symptoms in people with psychogenic non-epileptic seizures.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    An initial assessment is conducted to confirm the diagnosis of psychogenic non-epileptic seizures (CNEP) using video-EEG and to ensure the patient meets the inclusion criteria.

    A normal brain MRI is required as part of routine care before participation.

    The patient must stop any antidepressant treatment for two weeks (or five weeks for fluoxetine) prior to the administration of psilocybin.

  2. Step 2

    Baseline evaluation

    Three days before the administration of psilocybin (D-3), a functional brain MRI is performed to assess the activity of brain regions associated with cognitive control during an emotional Go-No Go task.

    Resting-state functional brain MRI is also conducted to evaluate the cognitive control network and the Default-Mode Network (DMN).

    The number of errors and response latency during both emotional and neutral Go-No Go tasks are recorded.

    The frequency of CNEP is measured using a seizure diary for the three months prior to psilocybin administration.

    The CGI-CNEP scale and dissociative symptomatology using the DES scale are assessed.

  3. Step 3

    Psilocybin administration

    On day 0 (D0), a single dose of psilocybin is administered orally in the form of a capsule.

    The 5D-ASC (5-Dimensional Altered States of Consciousness Questionnaire) is administered to evaluate the patient's experience.

  4. Step 4

    Post-administration evaluation

    Five days after psilocybin administration (D+5), the same assessments conducted at baseline are repeated.

    Functional brain MRI is performed again to measure changes in brain activity during the emotional Go-No Go task and in resting-state networks.

    The number of errors and response latency during the tasks are recorded again.

    The CGI-CNEP scale and dissociative symptomatology are reassessed.

    The 5D-ASC questionnaire is administered again.

  5. Step 5

    Follow-up assessments

    Follow-up assessments are conducted at one month (M1) and three months (M3) after psilocybin administration.

    The CGI-CNEP scale and dissociative symptomatology are measured again.

    The 5D-ASC questionnaire is administered at each follow-up.

Who can join the trial?

10 criteria

  • The patient must be in a stable mood, as determined by a specific questionnaire called the MINI.
  • The patient should be able to speak and understand French.
  • The patient must have a confirmed diagnosis of **psychogenic non-epileptic seizures** (CNEP) through a test called video-EEG, and the condition should have been present for more than 3 months, meeting specific criteria known as DSM-5.
  • The patient should have a normal brain MRI scan during the initial evaluation, which is part of routine care.
  • The patient must not have any issues with stopping antidepressant medication for two weeks (or five weeks if taking fluoxetine) before receiving **psilocybin**. Other mental health medications will not be stopped.
  • The patient must have signed a consent form agreeing to participate in the study.
  • The patient should be part of or have a health insurance plan.
  • The patient must be an adult, at least 18 years old and under 60 years old.
  • The patient should be available for follow-up for 6 months.
  • The patient must be in good physical health and not have any unstable medical conditions. These conditions include heart-related issues like a history of stroke, heart attack, heart failure, irregular heartbeat, or uncontrolled high blood pressure; epilepsy and active neurological issues; hormone-related problems like thyroid issues, adrenal gland problems, type I diabetes or insulin-dependent type II diabetes, or a history of severe low blood sugar requiring hospital treatment; significant liver problems; **glaucoma**; and issues with the prostate or bladder.

Who cannot join the trial?

4 criteria

  • Individuals with a history of **psychogenic non-epileptic seizures** cannot participate. These are episodes that look like seizures but are not caused by electrical activity in the brain.
  • Participants must be within a specific age range, which is not specified here.
  • Both **male** and **female** participants are eligible, but certain criteria may exclude some individuals.
  • Individuals considered part of a **vulnerable population** are not eligible. This term generally refers to groups who may have limited ability to protect their own interests, such as children or those with certain disabilities.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Psilocybin is a substance being studied for its potential effects on the brain, particularly in how it might influence cognitive control. In this trial, researchers are interested in understanding how a single dose of psilocybin affects brain activity in patients with psychogenic nonepileptic seizures (CNEP). The study uses brain imaging techniques to observe changes in brain regions that are involved in managing emotions and decision-making tasks.

What is already known about the treatment

Psilocybin – Psilocybin is administered orally, typically in the form of capsules or tablets. It is currently being studied in clinical trials for its potential effects on brain activity, particularly in patients with psychogenic non-epileptic seizures. The main therapeutic indication being explored is its ability to influence cognitive control and emotional processing. At the molecular level, psilocybin works by interacting with serotonin receptors in the brain, which can alter perception and mood. It is classified as a psychedelic compound and is being researched for its potential therapeutic benefits in various mental health conditions.

Investigated diseases

Psychogenic Non-Epileptic Seizures – These are episodes that resemble epileptic seizures but are not caused by electrical disruptions in the brain. Instead, they are often linked to psychological factors, such as stress or trauma. During an episode, a person may experience convulsions, loss of consciousness, or other seizure-like symptoms. Unlike epileptic seizures, these episodes do not show abnormal brain activity on an EEG. The condition can be challenging to diagnose because the symptoms mimic those of epilepsy. Understanding and addressing the underlying psychological issues is crucial for managing this condition.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2023-509679-17-00Protocol codeNIMAO/2022-2/IC-01Estimated enrolment10 patientsSponsorCentre Hospitalier Universitaire De Nimes

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).